A pharmacotherapy of atrial fibrillation in subclinical thyrotoxicosis

Известия высших учебных заведений. Поволжский регион: Медицинские науки

F.K. Rakhmatullov¹  I.Ya. Moiseeva¹  R.F. Rakhmatullov¹  L.V. Mel'nikova² 

[1] Penza State University;

[2] Russian Medical Academy of Continuous Professional Education;

关键词: subclinical thyrotoxicosis;    atrial fibrillation;    thiamazole;    bisoprolol;    sotalol;   

DOI  :  10.21685/2072-3032-2021-2-4

来源: DOAJ

【 摘 要 】

Background. Pharmacological therapy of atrial fibrillation (AF) in subclinicaldysfunction of the thyroid – is the most important problem of modern clinical medicine.The purpose of the study is to conduct a complex assessment of electrophysiological indicatorsof the heart and lipid profile in patients with subclinical thyrotoxicosis and paroxysmalAF during antiarrhythmic and thyrostatic therapy. Pharmacological therapy of atrial fibrillation (AF) in subclinical dysfunction of the thyroid is the most important problem of modernclinical medicine. Materials and methods. 126 patients with frequent paroxysms of AF withsubclinical thyrotoxicosis were examined. All patients underwent ECG control, EP study, assessmentof thyroid hormones level and lipid profile. Therapy included treatment with bisoprolol,sotalol, thiamazole and their combinations. Results. Electrophysiological predictorsof AF in subclinical thyrotoxicosis were identified. It was found that euthyroid status does notreduce a number of spontaneous paroxysms of AF. High antiarrhythmic efficacy of combineduse of bisoprolol with thiamazole and sotalol with thiamazole has been proven.